Group Information: A list of the researchers of the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing (AIBL) are provided at http://aibl.csiro.au/. A complete listing of the investigators of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. A list of the investigators of the Alzheimer’s Disease Cooperative Study (ADCS) are provided at http://adcs.org/.
Accepted for Publication: March 20, 2014.
Published Online: June 2, 2014. doi:10.1001/jamaneurol.2014.803.
Study concept and design: Donohue, Sperling, Salmon, Raman, Aisen.
Acquisition, analysis, or interpretation of data: Donohue, Sperling, Rentz, Thomas, Weiner, Aisen.
Drafting of the manuscript: Donohue, Sperling.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Donohue, Aisen.
Obtained funding: Weiner, Aisen.
Administrative, technical, or material support: Salmon, Thomas, Aisen.
Study supervision: Sperling, Rentz, Weiner, Aisen.
Conflict of Interest Disclosures: Drs Donohue and Salmon are consultants for Bristol-Myers Squibb. Dr Aisen serves on a scientific advisory board for NeuroPhage; has served as a consultant to Elan, Wyeth, Eisai, Schering-Plough, Bristol-Myers Squibb, Eli Lilly, NeuroPhage, Merck, Roche, Amgen, Genentech, Abbott, Pfizer, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, Medivation, Ichor, Toyama, Lundbeck, Biogen Idec, iPerian, Probiodrug, Somaxon, Biotie, Cardeus, Anavex, Kyowa Hakko Kirin Pharma, and Medtronic; and receives research support from Eli Lilly. Dr Sperling is funded by Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Janssen, Lundbeck, Merck, and Roche.
Funding/Support: Dr Donohue was supported by National Institute on Aging grant U01-AG10483 (principal investigator) funded by the National Institutes of Health. Dr Donohue was funded by grant 1KL2RR031978 from the National Institutes of Health and was supported by the generous contributions from Abbott; AC Immune; the Alzheimer’s Association; the Alzheimer’s Diseases Research Center; the University of California, San Diego; the Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences; Araclon; AstraZeneca; Avid Radiopharmaceuticals; Bayer HealthCare; BioClinica; Biogen Idec; Bristol-Myers Squibb; Eisai; Elan; Eli Lilly; F. Hoffmann–La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics NV; IXICO; Janssen Alzheimer Immunotherapy Research and Development, LLC; Johnson & Johnson Pharmaceutical Research and Development LLC; Kenes, International; Medpace; Merck; Meso Scale Diagnostics, LLC; National Brain Research Center, India, for Johns Hopkins Medicine; New York Academy of Sciences; Novartis; Pfizer; sanofi-aventis; Servier; Smartfish AS; Synarc; Takeda; and the University of Californa, Los Angeles.
Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: Data used in the preparation of this article were obtained from AIBL and were made available at the ADNI database. The AIBL researchers contributed data but did not participate in the analysis or writing of this report. The investigators within ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the ADCS at the University of California, San Diego. The Laboratory for Neuroimaging at the University of Southern California disseminates ADNI data (http://www.loni.usc.edu). The data collection and sharing for this project were funded by ADNI. The Canadian Institutes of Health Research are providing funds to support ADNI clinical sites in Canada. For AIBL, the design and conduct of the study and the collection and management of the data are funded by the Commonwealth Scientific and Industrial Research Organisation. For the ADCS-PI study, the design and conduct of study; the collection and management of the data; the analysis and interpretation of the data; and the preparation, review, and approval of the manuscript were supported by the National Institute on Aging/National Institutes.
Additional Contributions: We would like to acknowledge the invaluable contributions of our ADCS and ADNI collaborators, coinvestigators, volunteers, and their families, none of whom were financially compensated for their work.